Sparsentan information

Sparsentan
Clinical data
Trade names	Filspari
AHFS/Drugs.com	Monograph
MedlinePlus	a623018
License data	US DailyMed: Sparsentan;
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	254740-64-2;
DrugBank	DB12548;
UNII	9242RO5URM;
KEGG	D11776;
ChEBI	CHEBI:229526;
Chemical and physical data
3D model (JSmol)	Interactive image;
	SMILES CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C;
	InChI InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35); Key:WRFHGDPIDHPWIQ-UHFFFAOYSA-N;

Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy.^[1] Sparsentan is an endothelin and angiotensin II receptor antagonist.^[1]^[3] It is taken by mouth.^[1]

It was approved for medical use in the United States in February 2023.^[1]^[4]^[5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[6]

^ ^a ^b ^c ^d ^e "Filspari- sparsentan tablet, film coated". DailyMed. 17 February 2023. Retrieved 6 March 2023.
^ Cite error: The named reference Filspari EPAR was invoked but never defined (see the help page).
^ Chiu AW, Bredenkamp N (September 2023). "Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist". The Annals of Pharmacotherapy: 10600280231198925. doi:10.1177/10600280231198925. PMID 37706310. S2CID 261743204.
^ "Travere Therapeutics Announces FDA Accelerated Approval of Filspari (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy" (Press release). Travere Therapeutics. 17 February 2023. Retrieved 17 February 2023 – via GlobeNewswire.
^ Syed YY (April 2023). "Sparsentan: First Approval". Drugs. 83 (6): 563–568. doi:10.1007/s40265-023-01864-x. PMC 10232600. PMID 37022667.
^ New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.

[Filspari_FDA_label-1] "Filspari- sparsentan tablet, film coated". DailyMed. 17 February 2023. Retrieved 6 March 2023.

[Filspari_EPAR-2] Cite error: The named reference Filspari EPAR was invoked but never defined (see the help page).

[pmid37706310-3] Chiu AW, Bredenkamp N (September 2023). "Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist". The Annals of Pharmacotherapy: 10600280231198925. doi:10.1177/10600280231198925. PMID 37706310. S2CID 261743204.

[4] "Travere Therapeutics Announces FDA Accelerated Approval of Filspari (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy" (Press release). Travere Therapeutics. 17 February 2023. Retrieved 17 February 2023 – via GlobeNewswire.

[pmid37022667-5] Syed YY (April 2023). "Sparsentan: First Approval". Drugs. 83 (6): 563–568. doi:10.1007/s40265-023-01864-x. PMC 10232600. PMID 37022667.

[6] New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.

Sparsentan information

and 25 Related for: Sparsentan information

Sparsentan

Endothelin receptor antagonist

Losartan

Lisinopril

Enalapril

ACE inhibitor

Irbesartan

Discovery and development of ACE inhibitors

Valsartan

Ramipril

Perindopril

Renin

Olmesartan

Candesartan

Telmisartan

Benazepril

Captopril

Quinapril

CSL Vifor

Angiotensin II receptor blocker

Trandolapril

Angiotensin

Fosinopril

Angiotensin II receptor type 1

Aliskiren